Switch to:
Also traded in: Denmark, Germany, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 90.39
NYSE:NVO's Cash-to-Debt is ranked higher than
51% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. NYSE:NVO: 90.39 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:NVO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 3.88 Max: 90.39
Current: 90.39
0.29
90.39
Equity-to-Asset 0.46
NYSE:NVO's Equity-to-Asset is ranked lower than
71% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NYSE:NVO: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:NVO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.46  Med: 0.66 Max: 0.73
Current: 0.46
0.46
0.73
Interest Coverage 64.58
NYSE:NVO's Interest Coverage is ranked lower than
74% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NYSE:NVO: 64.58 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:NVO' s Interest Coverage Range Over the Past 10 Years
Min: 9.18  Med: 279.29 Max: 884.41
Current: 64.58
9.18
884.41
Piotroski F-Score: 5
Altman Z-Score: 10.50
Beneish M-Score: -2.86
WACC vs ROIC
11.45%
143.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 43.33
NYSE:NVO's Operating Margin % is ranked higher than
95% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. NYSE:NVO: 43.33 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:NVO' s Operating Margin % Range Over the Past 10 Years
Min: 21.38  Med: 35.7 Max: 45.81
Current: 43.33
21.38
45.81
Net Margin % 33.93
NYSE:NVO's Net Margin % is ranked higher than
93% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. NYSE:NVO: 33.93 )
Ranked among companies with meaningful Net Margin % only.
NYSE:NVO' s Net Margin % Range Over the Past 10 Years
Min: 20.38  Med: 26.62 Max: 33.93
Current: 33.93
20.38
33.93
ROE % 88.84
NYSE:NVO's ROE % is ranked higher than
99% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. NYSE:NVO: 88.84 )
Ranked among companies with meaningful ROE % only.
NYSE:NVO' s ROE % Range Over the Past 10 Years
Min: 27.38  Med: 50.43 Max: 88.84
Current: 88.84
27.38
88.84
ROA % 42.39
NYSE:NVO's ROA % is ranked higher than
98% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. NYSE:NVO: 42.39 )
Ranked among companies with meaningful ROA % only.
NYSE:NVO' s ROA % Range Over the Past 10 Years
Min: 18.46  Med: 30 Max: 42.39
Current: 42.39
18.46
42.39
ROC (Joel Greenblatt) % 177.27
NYSE:NVO's ROC (Joel Greenblatt) % is ranked higher than
96% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. NYSE:NVO: 177.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:NVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43  Med: 107.33 Max: 178.92
Current: 177.27
43
178.92
3-Year Revenue Growth Rate 12.40
NYSE:NVO's 3-Year Revenue Growth Rate is ranked higher than
63% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NYSE:NVO: 12.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:NVO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 8  Med: 14 Max: 127.9
Current: 12.4
8
127.9
3-Year EBITDA Growth Rate 15.30
NYSE:NVO's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NYSE:NVO: 15.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:NVO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 9.6  Med: 16.7 Max: 130.3
Current: 15.3
9.6
130.3
3-Year EPS without NRI Growth Rate 17.00
NYSE:NVO's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NYSE:NVO: 17.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:NVO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 10.2  Med: 20.4 Max: 36.9
Current: 17
10.2
36.9
GuruFocus has detected 1 Warning Sign with Novo Nordisk A/S $NYSE:NVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:NVO's 10-Y Financials

Financials (Next Earnings Date: 2017-05-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NVO Guru Trades in Q1 2016

Jeremy Grantham 122,600 sh (New)
Ruane Cunniff 97,525 sh (+19.93%)
Mario Gabelli 6,225 sh (+0.24%)
Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,787 sh (-0.51%)
Jim Simons 12,775,700 sh (-0.95%)
Ken Fisher 11,178,809 sh (-2.35%)
Spiros Segalas 6,179,837 sh (-16.07%)
» More
Q2 2016

NVO Guru Trades in Q2 2016

Jim Simons 12,949,800 sh (+1.36%)
Tom Gayner 1,075,000 sh (unchged)
Spiros Segalas 6,179,837 sh (unchged)
Murray Stahl 7,740 sh (-0.60%)
Mario Gabelli 6,176 sh (-0.79%)
Ken Fisher 10,963,094 sh (-1.93%)
Ruane Cunniff 94,165 sh (-3.45%)
Jeremy Grantham 87,600 sh (-28.55%)
» More
Q3 2016

NVO Guru Trades in Q3 2016

Jim Simons 14,653,500 sh (+13.16%)
Murray Stahl 7,787 sh (+0.61%)
Spiros Segalas 7,212,304 sh (+16.71%)
Ruane Cunniff 94,165 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Mario Gabelli Sold Out
Ken Fisher 10,910,669 sh (-0.48%)
Jeremy Grantham 61,700 sh (-29.57%)
» More
Q4 2016

NVO Guru Trades in Q4 2016

Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,787 sh (unchged)
Jeremy Grantham Sold Out
Spiros Segalas Sold Out
Ken Fisher 10,621,538 sh (-2.65%)
Jim Simons 13,945,900 sh (-4.83%)
Ruane Cunniff 43,687 sh (-53.61%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:GILD, NAS:CELG, NAS:BIIB, NAS:SHPG, NAS:AMGN, OTCPK:CSLLY, NAS:REGN, NAS:INCY, OTCPK:ALIOY, NAS:ALXN, NAS:VRTX, NAS:BMRN, OTCPK:UCBJF, OTCPK:GMXAY, NAS:GRFS, OTCPK:NVZMY, NAS:SGEN, NAS:ALKS, NAS:JAZZ, NAS:TSRO » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NOVOB.Switzerland, 0QIU.UK, NONOF.USA,
Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes care and biopharmaceuticals.

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein-related therapies for hemophilia and other disorders.

Top Ranked Articles about Novo Nordisk A/S

Something Strange Is Going On With Oral Insulin Novo Nordisk recently abandoned program despite promising results
Something is rotten in the state of Denmark. Read more...
The PBM Empire Strikes Back Some of the largest pharmacy benefit managers are driving significant change in drug pricing
I had the privilege of speaking at the GuruFocus Conference in Omaha. The basis of my talk was finding value in health care. Read more...

Ratios

vs
industry
vs
history
PE Ratio 15.69
NVO's PE Ratio is ranked higher than
75% of the 272 Companies
in the Global Biotechnology industry.

( Industry Median: 27.67 vs. NVO: 15.69 )
Ranked among companies with meaningful PE Ratio only.
NVO' s PE Ratio Range Over the Past 10 Years
Min: 12.13  Med: 23.56 Max: 34.41
Current: 15.69
12.13
34.41
Forward PE Ratio 15.04
NVO's Forward PE Ratio is ranked higher than
65% of the 78 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. NVO: 15.04 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 15.69
NVO's PE Ratio without NRI is ranked higher than
77% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. NVO: 15.69 )
Ranked among companies with meaningful PE Ratio without NRI only.
NVO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.13  Med: 23.53 Max: 34.41
Current: 15.69
12.13
34.41
Price-to-Owner-Earnings 17.87
NVO's Price-to-Owner-Earnings is ranked higher than
65% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 26.25 vs. NVO: 17.87 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NVO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.81  Med: 27.82 Max: 59.57
Current: 17.87
13.81
59.57
PB Ratio 13.23
NVO's PB Ratio is ranked lower than
89% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. NVO: 13.23 )
Ranked among companies with meaningful PB Ratio only.
NVO' s PB Ratio Range Over the Past 10 Years
Min: 3.68  Med: 8.95 Max: 31.9
Current: 13.23
3.68
31.9
PS Ratio 5.33
NVO's PS Ratio is ranked higher than
70% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. NVO: 5.33 )
Ranked among companies with meaningful PS Ratio only.
NVO' s PS Ratio Range Over the Past 10 Years
Min: 2.8  Med: 5.8 Max: 11.01
Current: 5.33
2.8
11.01
Price-to-Free-Cash-Flow 14.85
NVO's Price-to-Free-Cash-Flow is ranked higher than
66% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 22.69 vs. NVO: 14.85 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NVO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.07  Med: 24.4 Max: 47.08
Current: 14.85
12.07
47.08
Price-to-Operating-Cash-Flow 12.31
NVO's Price-to-Operating-Cash-Flow is ranked higher than
70% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 23.59 vs. NVO: 12.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NVO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.91  Med: 19.82 Max: 32.54
Current: 12.31
9.91
32.54
EV-to-EBIT 11.90
NVO's EV-to-EBIT is ranked higher than
62% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. NVO: 11.90 )
Ranked among companies with meaningful EV-to-EBIT only.
NVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 16.7 Max: 25.7
Current: 11.9
9.2
25.7
EV-to-EBITDA 11.16
NVO's EV-to-EBITDA is ranked higher than
61% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. NVO: 11.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 16.1 Max: 23.6
Current: 11.16
8.2
23.6
PEG Ratio 0.91
NVO's PEG Ratio is ranked higher than
73% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NVO: 0.91 )
Ranked among companies with meaningful PEG Ratio only.
NVO' s PEG Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.48 Max: 5.14
Current: 0.91
0.66
5.14
Shiller PE Ratio 29.33
NVO's Shiller PE Ratio is ranked higher than
76% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 50.93 vs. NVO: 29.33 )
Ranked among companies with meaningful Shiller PE Ratio only.
NVO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.23  Med: 43.96 Max: 67.69
Current: 29.33
23.23
67.69
Current Ratio 1.26
NVO's Current Ratio is ranked lower than
84% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. NVO: 1.26 )
Ranked among companies with meaningful Current Ratio only.
NVO' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.14 Max: 2.45
Current: 1.26
1.26
2.45
Quick Ratio 0.96
NVO's Quick Ratio is ranked lower than
86% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. NVO: 0.96 )
Ranked among companies with meaningful Quick Ratio only.
NVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.45 Max: 1.91
Current: 0.96
0.96
1.91
Days Inventory 288.81
NVO's Days Inventory is ranked lower than
84% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. NVO: 288.81 )
Ranked among companies with meaningful Days Inventory only.
NVO' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 282.52 Max: 343.56
Current: 288.81
246.45
343.56
Days Sales Outstanding 66.07
NVO's Days Sales Outstanding is ranked lower than
55% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. NVO: 66.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.9 Max: 66.07
Current: 66.07
45.09
66.07
Days Payable 127.69
NVO's Days Payable is ranked higher than
71% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 59.13 vs. NVO: 127.69 )
Ranked among companies with meaningful Days Payable only.
NVO' s Days Payable Range Over the Past 10 Years
Min: 72.54  Med: 100.02 Max: 127.69
Current: 127.69
72.54
127.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.17
NVO's Dividend Yield % is ranked higher than
89% of the 223 Companies
in the Global Biotechnology industry.

( Industry Median: 1.29 vs. NVO: 4.17 )
Ranked among companies with meaningful Dividend Yield % only.
NVO' s Dividend Yield % Range Over the Past 10 Years
Min: 0.93  Med: 1.57 Max: 4.19
Current: 4.17
0.93
4.19
Dividend Payout Ratio 0.63
NVO's Dividend Payout Ratio is ranked lower than
81% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. NVO: 0.63 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NVO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.35 Max: 0.63
Current: 0.63
0.26
0.63
3-Year Dividend Growth Rate 37.70
NVO's 3-Year Dividend Growth Rate is ranked higher than
88% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 8.70 vs. NVO: 37.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NVO' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 12.7  Med: 28.9 Max: 37.7
Current: 37.7
12.7
37.7
Forward Dividend Yield % 3.32
NVO's Forward Dividend Yield % is ranked higher than
91% of the 208 Companies
in the Global Biotechnology industry.

( Industry Median: 1.22 vs. NVO: 3.32 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 16.65
NVO's 5-Year Yield-on-Cost % is ranked higher than
60% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. NVO: 16.65 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.71  Med: 6.27 Max: 16.73
Current: 16.65
3.71
16.73
3-Year Average Share Buyback Ratio 1.80
NVO's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. NVO: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 1.5 Max: 8
Current: 1.8
-3.1
8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 80.71
NVO's Price-to-Net-Current-Asset-Value is ranked lower than
98% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. NVO: 80.71 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NVO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 11.62  Med: 24.24 Max: 100.73
Current: 80.71
11.62
100.73
Price-to-Tangible-Book 14.07
NVO's Price-to-Tangible-Book is ranked lower than
86% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. NVO: 14.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 6.39 Max: 23.2
Current: 14.07
3.14
23.2
Price-to-Intrinsic-Value-Projected-FCF 1.38
NVO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
77% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.22 vs. NVO: 1.38 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NVO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.37  Med: 2.5 Max: 7.38
Current: 1.38
1.37
7.38
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.55
NVO's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
95% of the 19 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. NVO: 0.55 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.92
NVO's Price-to-Median-PS-Value is ranked higher than
59% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. NVO: 0.92 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 0.86 Max: 1.65
Current: 0.92
0.5
1.65
Price-to-Peter-Lynch-Fair-Value 0.80
NVO's Price-to-Peter-Lynch-Fair-Value is ranked higher than
82% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.48 vs. NVO: 0.80 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
NVO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.02 Max: 3.78
Current: 0.8
0.27
3.78
Price-to-Graham-Number 3.13
NVO's Price-to-Graham-Number is ranked lower than
63% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.54 vs. NVO: 3.13 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NVO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.56  Med: 2.8 Max: 5.52
Current: 3.13
1.56
5.52
Earnings Yield (Greenblatt) % 8.42
NVO's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. NVO: 8.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.9  Med: 6 Max: 10.8
Current: 8.42
3.9
10.8
Forward Rate of Return (Yacktman) % 24.15
NVO's Forward Rate of Return (Yacktman) % is ranked higher than
65% of the 124 Companies
in the Global Biotechnology industry.

( Industry Median: 15.21 vs. NVO: 24.15 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NVO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.5  Med: 16.7 Max: 33.7
Current: 24.15
7.5
33.7

More Statistics

Revenue (TTM) (Mil) $16,551
EPS (TTM) $ 2.22
Beta0.74
Short Percentage of Float0.09%
52-Week Range $30.89 - 57.81
Shares Outstanding (Mil)2,550.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 16,422 17,623 17,992
EPS ($) 2.22 2.38 2.53
EPS without NRI ($) 2.22 2.38 2.53
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.75%
Dividends per Share ($) 1.23 1.55 1.67
» More Articles for NVO

Headlines

Articles On GuruFocus.com
New Features: Individual Portfolio Tracker and Value Screens Tracker Mar 03 2017 
While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017 
Beaten-Down Valuation and a 3% Dividend Yield Feb 07 2017 
Value Screeners Identify Top Sectors Feb 06 2017 
7 Stocks for 2017 Jan 20 2017 
Something Strange Is Going On With Oral Insulin Dec 23 2016 
Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
23 Questions With Thomas Macpherson of Nintai Partners Nov 21 2016 
Graham's 4 Vital Elements Nov 10 2016 
World Leader in Diabetes Medication Hits 2-Year Low Nov 07 2016 

More From Other Websites
Novo Nordisk Stock Trades Ex-Dividend Thursday Mar 22 2017
A drug company just struck a deal to discount the price of a lifesaving diabetes medication to $25 Mar 16 2017
Sanofi and Voluntis Ink Global Pact for Diabetes Mar 15 2017
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays Mar 13 2017
SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Novo Nordisk... Mar 11 2017
NOVO NORDISK 72 HOUR DEADLINE ALERT: APPROXIMATELY 72 HOURS REMAIN; FORMER LOUISIANA ATTORNEY... Mar 10 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novo... Mar 10 2017
Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of... Mar 10 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Action... Mar 10 2017
Here’s Our Take On The Global Blood Therapeutics Inc (GBT) Rumors Mar 10 2017
Biotech Reporter Adam Feuerstein Will Be On Benzinga's PreMarket Prep Friday Morning Mar 09 2017
Novo Nordisk in Talks to Buy Global Blood Therapeutics (NVO,GBT) Mar 09 2017
March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Novo Nordisk A/S Investors of... Mar 09 2017
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novo... Mar 09 2017
Novo Nordisk Named on the FORTUNE 100 Best Companies to Work For® List for Ninth Consecutive Year Mar 09 2017
Global Blood Therapeutics Shares Jump on Report It Was Approached by Novo Nordisk Mar 08 2017
Novo Nordisk in bid for Global Blood Therapeutics - sources Mar 08 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Action... Mar 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)